
Lilly signs $375M deal with government for experimental COVID-19 treatment
Eli Lilly and Co. said Wednesday that the U.S. government will accept 300,000 vials of the drug, called bamlanivimab, if the Food and Drug Administration grants emergency authorization for its use.